Proteinuria in Lupus Nephritis: When to Biopsy and How to Interpret a "Partial" Response
A 29-year-old woman with SLE diagnosed 2 years ago presents with new lower-extremity edema. Current medications: hydroxychloroquine, mycophenolate mofetil 1 g twice daily, prednisone 5 mg daily. BP 148/92. Labs: serum creatinine 1.3 mg/dL (baseline 0.8), urine protein-to-creatinine ratio 2.8 g/g (was 0.2 six months ago), albumin 2.6 g/dL, C3 low, C4 low, anti-dsDNA rising. Urinalysis shows 3+ protein, 10–15 RBC/hpf, and RBC casts. She has no active infection and no thrombosis symptoms.
1. Does she need a kidney biopsy now, and what will you look for on it?
Read the worked answer
Yes - this is a new, active nephritic-nephrotic flare (rising proteinuria, declining eGFR, active sediment with RBC casts, low complement, rising dsDNA) in a patient already on immunosuppression, and biopsy is indicated to guide therapy. Biopsy distinguishes proliferative (class III/IV) lupus nephritis, which needs aggressive induction (high-dose steroids plus mycophenolate or cyclophosphamide, with biopsy-based choice), from pure membranous (class V), which is managed differently, and from non-immune causes (thrombotic microangiopathy, podocytopathy). It also grades activity vs chronicity (NIH activity/chronicity indices), which informs prognosis and whether aggressive therapy is worthwhile. Important nuance: she is already on MMF - a biopsy showing active proliferative disease despite MMF suggests inadequate dosing/adherence or a need to switch induction agent, whereas a purely chronic/sclerosed picture argues against escalating immunosuppression. Send complement, dsDNA, and consider antiphospholipid testing; control BP.
2. Biopsy shows class IV-G (A) lupus nephritis with moderate activity and little chronicity. She completes 6 months of induction with high-dose steroids plus MMF and improves: proteinuria falls from 2.8 to 1.1 g/g, creatinine back to 0.9, complement normalizing. How do you judge response and what do you do next?
Read the worked answer
This is a partial renal response, not complete: proteinuria has fallen substantially (>50%) and renal function normalized, but UPCR remains >0.5–0.7 g/g. Partial response at 6 months is meaningful and predicts better long-term outcomes, but it warrants optimization rather than declaring victory. Steps: (1) confirm adherence and correct measurement (first-morning urine, rule out orthostatic/infection); (2) maximize renin-angiotensin blockade (ACEi/ARB titrated to tolerated dose), BP target <130/80, and add an SGLT2 inhibitor if appropriate; (3) continue MMF at tolerated dose and taper steroids to lowest effective dose; (4) continue hydroxychloroquine. Reassess at 12 months - if proteinuria is not approaching complete response (<0.5–0.7 g/g) or is rising, consider repeat biopsy to distinguish ongoing activity from chronic damage before changing therapy. Do not stop immunosuppression based on a partial response alone.